menu
    • menu
    [{"orgOrder":0,"company":"Ambio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ambio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ambio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ambio \/ Undisclosed"},{"orgOrder":0,"company":"Ambio","sponsor":"Apotex Fermentation Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ambio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ambio \/ Ambio","highestDevelopmentStatusID":"15","companyTruncated":"Ambio \/ Ambio"}]

    Find Clinical Drug Pipeline Developments & Deals by Ambio

    Menu

    Ambio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ambio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ambio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ambio Announces US FDA Approval of a Generic Version of Forteo® (Teriparatide Injection) for Its Partner Apot...

                            Details : Forteo-Generic (teriparatide) is a parathyroid hormone analog, (PTH 1-34), which is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                            Product Name : Forteo-Generic

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 01, 2023

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ambio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ambio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Recipient : Apotex Fermentation Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States

                            Details : Teriparatide Injection, a single-patient-use pre-filled pen and a parathyroid hormone analog, is used for the treatment of osteoporosis in the United States.

                            Product Name : Teriparatide-Generic

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            November 21, 2023

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Recipient : Apotex Fermentation Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth